Treace Medical Concepts (TMCI) Revenue (2020 - 2026)

Treace Medical Concepts (TMCI) has reported Revenue for 7 consecutive years, with $45.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue fell 4.24% year-over-year to $45.4 million; the trailing twelve-month figure through Jun 2026 stood at $205.3 million (down 3.95% YoY), and the FY2025 full-year result was $212.7 million, up 1.59% from the prior year.
• Revenue eased to $45.4 million in Q2 2026 per TMCI's latest filing, from $47.2 million in the prior quarter.
• Across five years, Revenue topped out at $68.7 million in Q4 2024 and bottomed at $29.0 million in Q1 2022.
• Historically, Revenue has averaged $46.9 million across 5 years, with a median of $46.3 million in 2026.
• The sharpest annual moves came in 2022 and 2026: Revenue surged 55.27% in 2022, then dropped 10.22% in 2026.
• Over 5 years, Revenue stood at $49.8 million in 2022, then climbed by 25.0% to $62.2 million in 2023, then climbed by 10.44% to $68.7 million in 2024, then retreated by 9.01% to $62.5 million in 2025, then retreated by 27.42% to $45.4 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $45.4 million, $47.2 million, and $62.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.